UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The interplay between autophagy and ROS in tumorigenesis

Frontiers in oncology, 2012, Vol.2, p.171

2012

Volltextzugriff (PDF)

Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial

The lancet oncology, 2019-03, Vol.20 (3), p.371-382

2019

Volltextzugriff (PDF)

Role and regulation of autophagy in cancer

Biochimica et biophysica acta, 2009-09, Vol.1793 (9), p.1516-1523

2009

Volltextzugriff (PDF)

Chapter 4 A Mouse Mammary Epithelial Cell Model to Identify Molecular Mechanisms Regulating Breast Cancer Progression

Methods in Enzymology, 2008, Vol.446, p.61-76

2008

Volltextzugriff (PDF)

Autophagy regulator BECN1 suppresses mammary tumorigenesis driven by WNT1 activation and following parity

Autophagy, 2014-11, Vol.10 (11), p.2036-2052

2014

Volltextzugriff (PDF)

Role of autophagy in cancer

Nature reviews. Cancer, 2007-12, Vol.7 (12), p.961-967

2007

Volltextzugriff (PDF)

Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis

Cancer research (Chicago, Ill.), 2020-12, Vol.80 (24), p.5427-5434

2020

Volltextzugriff (PDF)

Bcl-2 Modulation to Activate Apoptosis in Prostate Cancer

Molecular cancer research, 2009-09, Vol.7 (9), p.1487-1496

2009

Volltextzugriff (PDF)

Pembrolizumab plus chemotherapy in triple-negative breast cancer – Authors' reply

The Lancet (British edition), 2021-07, Vol.398 (10294), p.24-25

2021

Volltextzugriff (PDF)

Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study

Clinical cancer research, 2021-06, Vol.27 (11), p.3061-3068

2021

Volltextzugriff (PDF)

Abstract CT069: KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC)

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.CT069-CT069

2017

Volltextzugriff (PDF)

Autophagy opposes p53-mediated tumor barrier to facilitate tumorigenesis in a model of PALB2-associated hereditary breast cancer

Cancer discovery, 2013-08, Vol.3 (8), p.894-907

2013

Volltextzugriff (PDF)

Prevalence, treatment patterns, and prognosis of low estrogen receptor-positive

Breast cancer research and treatment, 2021-10, Vol.189 (3), p.653

2021

Volltextzugriff (PDF)

Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer

The New England journal of medicine, 2024-09

2024

Volltextzugriff (PDF)

Association between event-free survival and overall survival in early-stage triple-negative breast cancer

Future oncology (London, England), 2024-02, Vol.20 (6), p.335-348

2024

Volltextzugriff (PDF)

Time-restricted feeding and the realignment of biological rhythms: translational opportunities and challenges

Journal of translational medicine, 2014-03, Vol.12 (1), p.79-79, Article 79

2014

Volltextzugriff (PDF)

Evaluation of Pathologic Complete Response as a Surrogate for Long-Term Survival Outcomes in Triple-Negative Breast Cancer

Journal of the National Comprehensive Cancer Network, 2020-08, Vol.18 (8), p.1096-1104

2020

Volltextzugriff (PDF)

ERBB2 overexpression suppresses stress-induced autophagy and renders ERBB2-induced mammary tumorigenesis independent of monoallelic Becn1 loss

Autophagy, 2014-04, Vol.10 (4), p.662-676

2014

Volltextzugriff (PDF)

Chapter 4 Assessing Metabolic Stress and Autophagy Status in Epithelial Tumors

Methods in Enzymology, 2009, Vol.453, p.53-81

2009

Volltextzugriff (PDF)

Abstract OT-30-01: KEYLYNK-009: A phase 2/3, open-label, randomized study of pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with first-line pembrolizumab plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.OT-30-01-OT-30-01

2021

Volltextzugriff (PDF)

Abstract PS12-01: Pembrolizumab versus chemotherapy for previously treated metastatic triple-negative breast cancer (KEYNOTE-119): Efficacy in patients with lung or liver metastases

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS12-01-PS12-01

2021

Volltextzugriff (PDF)

PS2-3 Neoadjuvant pembrolizumab/placebo + chemo, followed by adjuvant pembrolizumab/placebo in early TNBC: Asian subgroup

Annals of oncology, 2022-07, Vol.33, p.S465

2022

Volltextzugriff (PDF)

Abstract GS1-02: Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.GS1-02-GS1-02

2022

Volltextzugriff (PDF)

Abstract CT073: IMPRIME 1 (NCT02981303): A novel phase 2 study in second-line +, metastatic triple negative breast cancer patients shows promising clinical benefit for the combination of the immune checkpoint inhibitor, pembrolizumab (pembro), with the novel innate immune activator, Imprime PGG

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.CT073-CT073

2020

Volltextzugriff (PDF)

Abstract P2-09-05: Low estrogen receptor positive (1-10%) breast cancer prevalence, treatment patterns and prognosis: A single institution’s experience in Korea

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.P2-P2-09-05

2020

Volltextzugriff (PDF)

26 – 50 von 96

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieJournal Of Clinical Oncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(90)
Mit Volltextzugriff
(81)

Publikationsform

Sprache

Englisch
(96)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

The interplay between autophagy and ROS in tumorigenesis

Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial

Role and regulation of autophagy in cancer

Chapter 4 A Mouse Mammary Epithelial Cell Model to Identify Molecular Mechanisms Regulating Breast Cancer Progression

Autophagy regulator BECN1 suppresses mammary tumorigenesis driven by WNT1 activation and following parity

Role of autophagy in cancer

Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis

Bcl-2 Modulation to Activate Apoptosis in Prostate Cancer

Pembrolizumab plus chemotherapy in triple-negative breast cancer – Authors' reply

Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study

Abstract CT069: KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC)

Autophagy opposes p53-mediated tumor barrier to facilitate tumorigenesis in a model of PALB2-associated hereditary breast cancer

Prevalence, treatment patterns, and prognosis of low estrogen receptor-positive

Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer

Association between event-free survival and overall survival in early-stage triple-negative breast cancer

Time-restricted feeding and the realignment of biological rhythms: translational opportunities and challenges

Evaluation of Pathologic Complete Response as a Surrogate for Long-Term Survival Outcomes in Triple-Negative Breast Cancer

ERBB2 overexpression suppresses stress-induced autophagy and renders ERBB2-induced mammary tumorigenesis independent of monoallelic Becn1 loss

Chapter 4 Assessing Metabolic Stress and Autophagy Status in Epithelial Tumors

Abstract OT-30-01: KEYLYNK-009: A phase 2/3, open-label, randomized study of pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with first-line pembrolizumab plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)

Abstract PS12-01: Pembrolizumab versus chemotherapy for previously treated metastatic triple-negative breast cancer (KEYNOTE-119): Efficacy in patients with lung or liver metastases

PS2-3 Neoadjuvant pembrolizumab/placebo + chemo, followed by adjuvant pembrolizumab/placebo in early TNBC: Asian subgroup

Abstract GS1-02: Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer

Abstract CT073: IMPRIME 1 (NCT02981303): A novel phase 2 study in second-line +, metastatic triple negative breast cancer patients shows promising clinical benefit for the combination of the immune checkpoint inhibitor, pembrolizumab (pembro), with the novel innate immune activator, Imprime PGG

Abstract P2-09-05: Low estrogen receptor positive (1-10%) breast cancer prevalence, treatment patterns and prognosis: A single institution’s experience in Korea

Aktive Filter

Suchergebnisse filtern